scholarly article | Q13442814 |
P356 | DOI | 10.1038/S41374-019-0307-9 |
P698 | PubMed publication ID | 31439892 |
P2093 | author name string | Na Chen | |
Bing Liu | |||
Jing Cui | |||
Jingyuan Song | |||
Hetian Lei | |||
Jingxiang Zhong | |||
Haote Han | |||
Joanne Aiko Matsubara | |||
Zhengping Hu | |||
P2860 | cites work | Interaction between the retinoblastoma protein and the oncoprotein MDM2 | Q24323385 |
Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye | Q24625311 | ||
Clinical Overview of MDM2/X-Targeted Therapies | Q26767402 | ||
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
MDM2--master regulator of the p53 tumor suppressor protein | Q28138926 | ||
Genome editing. The new frontier of genome engineering with CRISPR-Cas9 | Q28252298 | ||
Amplification of a gene encoding a p53-associated protein in human sarcomas | Q28270924 | ||
RNA-guided gene activation by CRISPR-Cas9-based transcription factors | Q28295458 | ||
p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases | Q28611425 | ||
CRISPR-Cas systems for editing, regulating and targeting genomes | Q29615781 | ||
Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression | Q29615784 | ||
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 | Q29615851 | ||
Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells. | Q30356570 | ||
Novel sequential ChIP and simplified basic ChIP protocols for promoter co-occupancy and target gene identification in human embryonic stem cells | Q33475969 | ||
TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer | Q33559621 | ||
Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis | Q33601591 | ||
The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor | Q34030117 | ||
Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy | Q34429965 | ||
Proliferative vitreoretinopathy: risk factors and pathobiology | Q34572836 | ||
Inhibitory effects of resveratrol on PDGF-BB-induced retinal pigment epithelial cell migration via PDGFRβ, PI3K/Akt and MAPK pathways | Q34607101 | ||
Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology | Q34724376 | ||
The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy | Q35070151 | ||
Nutlin-3-induced redistribution of chromatin-bound IFI16 in human hepatocellular carcinoma cells in vitro is associated with p53 activation | Q35080124 | ||
In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9 | Q35820051 | ||
A novel function of p53: a gatekeeper of retinal detachment | Q36204186 | ||
Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements | Q36338669 | ||
Vascular Endothelial Cell Growth Factor A Acts via Platelet-Derived Growth Factor Receptor α To Promote Viability of Cells Enduring Hypoxia. | Q37224171 | ||
Proliferative vitreoretinopathy: pathobiology and therapeutic targets | Q37448440 | ||
Editing VEGFR2 Blocks VEGF-Induced Activation of Akt and Tube Formation | Q37682513 | ||
The retinal pigment epithelium: an important player of retinal disorders and regeneration | Q38123624 | ||
Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53. | Q38710594 | ||
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. | Q38749151 | ||
The Role of MDM2 Amplification and Overexpression in Tumorigenesis | Q38837916 | ||
The Clustered, Regularly Interspaced, Short Palindromic Repeats-associated Endonuclease 9 (CRISPR/Cas9)-created MDM2 T309G Mutation Enhances Vitreous-induced Expression of MDM2 and Proliferation and Survival of Cells | Q39720539 | ||
Introduction of the MDM2 T309G Mutation in Primary Human Retinal Epithelial Cells Enhances Experimental Proliferative Vitreoretinopathy | Q42380716 | ||
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome | Q42734774 | ||
Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment: a prospective randomized multicenter clinical study | Q46869907 | ||
Role of epithelial-mesenchymal transition in proliferative vitreoretinopathy. | Q52666368 | ||
β-arrestin1-medieated inhibition of FOXO3a contributes to prostate cancer cell growth in vitro and in vivo. | Q55319952 | ||
MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner | Q56565980 | ||
Dependence of artesunate on long noncoding RNA-RP11 to inhibit epithelial-mesenchymal transition of hepatocellular carcinoma | Q58597865 | ||
Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11 | Q73167697 | ||
Proliferative vitreoretinopathy: an overview | Q77144020 | ||
LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation | Q89094868 | ||
The pathophysiology of proliferative vitreoretinopathy in its management | Q93588666 | ||
P433 | issue | 12 | |
P921 | main subject | Cas9 | Q16965677 |
P304 | page(s) | 1874-1886 | |
P577 | publication date | 2019-08-22 | |
P1433 | published in | Laboratory Investigation | Q6467260 |
P1476 | title | Blockade of MDM2 with inactive Cas9 prevents epithelial to mesenchymal transition in retinal pigment epithelial cells | |
P478 | volume | 99 |
Q89902210 | Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review | cites work | P2860 |
Search more.